CD274 and neoplasm: The combination of MRTX849 and pembrolizumab cleared the dose-limiting toxicity observation period in the phase I/II KRYSTAL-1 trial and is now formally entering the phase II stage, as the KRYSTAL-7 trial where MRTX849 will be combined with pembrolizumab in two arms, according to PD-L1 tumour proportion score.